The liquid biopsy market represents a significant change in how we identify and monitor cancer-related biomarkers. It represents a revolutionary approach to cancer diagnostics and monitoring. Liquid biopsy provides a non-invasive alternative to traditional biopsies by examining a patient’s biofluids, like blood or urine, to find tumor-derived DNA, circulating tumour cells (CTCs), and other biomolecules. …
Continue reading “Liquid Biopsy Market Projected to Surge Beyond US$ 4,126 Million by 2032”